Merck: boosted by pneumococcus vaccine
(CercleFinance.com) - Merck on Monday reported "encouraging" results from three studies evaluating the safety and immunogenicity of a proposed vaccine against pneumococcus in HIV-positive patients.
According to the US biopharmaceutical group, these trials showed that V114 provoked an immune response to the 15 serotypes planned and that it could be administered in addition to the influenza vaccine in patients over 50 years of age.
The laboratory says it is now considering filing a registration dossier for the vaccine.
Merck also announced on Monday that Keytruda, its flagship immunotherapy, has been approved in China for the second-line treatment of squamous cell carcinoma of the esophagus.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
According to the US biopharmaceutical group, these trials showed that V114 provoked an immune response to the 15 serotypes planned and that it could be administered in addition to the influenza vaccine in patients over 50 years of age.
The laboratory says it is now considering filing a registration dossier for the vaccine.
Merck also announced on Monday that Keytruda, its flagship immunotherapy, has been approved in China for the second-line treatment of squamous cell carcinoma of the esophagus.
Copyright (c) 2020 CercleFinance.com. All rights reserved.